Transport of Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1) variants to the red blood cell (RBC) surface enables malarial parasite evasion of host immunity by modifying the antigenic and adhesive properties of infected RBCs. In this study, we applied the Bxb1 integrase system to integrate transgenes encoding truncated PfEMP1-GFP fusions into cytoadherent A4 parasites and characterize their surface transport requirements. Our studies revealed that the semiconserved head structure of PfEMP1 proteins, in combination with the predicted transmembrane region and cytoplasmic tail, encodes sufficient information for RBC surface display. In contrast, miniPfEMP1 proteins with truncated head structures were exported to the RBC cytoplasm but were not detected at the RBC surface by flow cytometry or immuno-electron microscopy. We demonstrated the absence of a mechanistic barrier to having native and miniPfEMP1 proteins displayed simultaneously at the RBC surface. However, surface-exposed miniPfEMP1 proteins did not convey cytoadherence properties to their host cells, implicating potential steric considerations in host-receptor interactions or the need for multiple domains to mediate cell binding. This study establishes a new system to investigate PfEMP1 transport and demonstrates that the PfEMP1 semi-conserved head structure is under selection for protein transport, in addition to its known roles in adhesion.
Introduction
Clinical manifestations of malaria result from the asexual blood stage forms of Plasmodium parasites that undergo cycles of invasion, replication and egress of red blood cells (RBCs) (Miller et al., 2002) . RBCs are terminally differentiated cells that lack secretory organelles, and Plasmodium falciparum extensively modifies these host cells to enable growth inside a parasitophorous vacuole, acquire intracellular and extracellular nutrients, and allow infected RBCs to cytoadhere to host endothelium. This latter modification causes microvascular sequestration of infected RBCs, which thereby avoid clearance in the spleen. These requirements make it necessary for the parasite to elaborate a sophisticated extracellular trafficking machinery capable of transporting parasite proteins across the parasitophorous vacuole membrane (PVM) and to different destinations within the host cell, including to the RBC surface.
The mechanisms that facilitate trafficking are still incompletely understood; however, exported proteins usually have a N-terminal sequence (NTS) that is hydrophobic and directs them to the parasite endoplasmic reticulum (ER). A default trafficking pathway then transports them to the parasitophorous vacuole (Wickham et al., 2001; Lopez-Estrano et al., 2003) . Transport across the PVM is enabled by a five amino acid sequence called the P. falciparum Export Element (PEXEL) (Marti et al., 2004) or the Vacuolar Transport Signal (VTS) (Hiller et al., 2004) . Cleavage and acetylation of this sequence occurs in the ER (Chang et al., 2008; Boddey et al., 2009) . Protein export appears to involve unfolding of proteins in the parasitophorous vacuole (Gehde et al., 2009) and their subsequent movement through a translocon machinery embedded in the PVM (de Koning-Ward et al., 2009 ). Several models have been put forth to explain protein transport within the infected RBC (Templeton and Deitsch, 2005; Lingelbach and Przyborski, 2006) . These include transport through vesicles (Trelka et al., 2000) , complex membrane networks (Elmendorf et al., 1992; Wickert et al., 2003) or non-lipid enclosed protein aggregates (Knuepfer et al., 2005) . Many exported proteins associate with lipid enclosed structures known as Maurer's clefts, which appear to be protein-sorting points within the RBC (Wickham et al., 2001; Kriek et al., 2003) . Among the least understood aspects are the requirements for the final steps of protein transport to the infected RBC membrane.
A key molecule at the infected RBC surface is P. falciparum erythrocyte membrane protein 1 (PfEMP1), a large clonally variant adhesion protein (Baruch et al., 1995; Smith et al., 1995; Su et al., 1995) . This protein is anchored at parasite-induced, 'knob-like' protrusions at the RBC membrane where it can interact with host adhesins including CD36, intercellular adhesion molecule-1 (ICAM-1) or chondroitin sulfate A (CSA), enabling infected RBCs to sequester within the microvasculature (Kraemer and Smith, 2006) . The extracellular portion of PfEMP1 consists of multiple adhesion domains, classified as Duffy binding-like (DBL) domains or cysteine-rich interdomain regions (CIDR), which are highly variable between family members. The resulting, distinct adhesion properties can lead to widely different clinical outcomes, including cerebral or placental malaria (Miller et al., 2002) . Although variable in sequence and domain composition, nearly all PfEMP1 proteins have a semi-conserved protein 'head structure' consisting of an~60 amino acid N-terminal segment and a DBL and CIDR tandem domain (Gardner et al., 2002; Kraemer et al., 2007) . This region of the protein appears to be under strong selection for host receptor binding (Robinson et al., 2003) and may have a role in protein transport (Hiller et al., 2004; Marti et al., 2004) . In contrast to the extracellular region, the PfEMP1 cytoplasmic tail is relatively conserved, and interacts with knob-associated histidine-rich protein (KAHRP) and potentially with the RBC cytoskeleton proteins actin and spectrin at the knobs (Kilejian et al., 1991; Waller et al., 1999; 2002; Oh et al., 2000) .
The sequence requirements for PfEMP1 surface display are incompletely understood. Unlike most exported proteins, PfEMP1 lacks an N-terminal hydrophobic signal sequence that directs proteins to the ER for further export. The PfEMP1 transmembrane (TM) domain might potentially fulfil this trafficking role (Knuepfer et al., 2005) . In addition, two different PEXEL-like motifs have been proposed to reside in the PfEMP1 N-terminus (Hiller et al., 2004; Marti et al., 2004) . Recently, trafficking to the RBC surface was achieved by expressing a chimeric protein consisting of a PfEMP1 TM and C-terminal sequence fused to an upstream 120 amino acid sequence from KAHRP (Knuepfer et al., 2005) . The KAHRP region presumably provided an N-terminal hydrophobic signal sequence that is not present in the native PfEMP1 protein and a PEXEL element for protein export. Nevertheless, the native sequence requirements for PfEMP1 display at the infected RBC surface have remained uncharacterized.
The PfEMP1s are encoded by the heterogeneous family of var genes, present at~60 copies per P. falciparum genome. These operate under an allelic exclusion mechanism that prevents expression of more than a single var gene per parasite and enables parasites to switch expression between different var genes (Scherf et al., 1998; Frank and Deitsch, 2006) . It has not been clear whether mechanistic barriers preclude having two PfEMP1 proteins simultaneously displayed at the RBC surface, a situation that could potentially occur in multiply infected RBCs. Although highly variable, PfEMP1 proteins are major targets of acquired host immunity, and represent prime candidates for a pregnancy-associated malaria vaccine (Salanti et al., 2004) and other potential therapeutic interventions. A system that would enable the study of PfEMP1 transport and exposure at the RBC surface would therefore be of clear benefit. However, genetic engineering approaches to analyse var genes face a range of problems. Most var genes average 8-10 kb in length, making it technically challenging to episomally express the full-length sequences from transgene expression plasmids. Allelic exchange strategies have been used to disrupt specific var genes by single or double recombination (Andrews et al., 2003; Horrocks et al., 2004; Viebig et al., 2005) , but the large size of these genes and their switching properties have hindered structure-function studies and phenotypic analysis.
In this study, we have established a transgenic system, based on Bxb1 integrase-mediated recombination , which enables truncated PfEMP1-GFP fusions or miniPfEMP1-GFP proteins to be expressed from attP containing mini-var plasmids integrated into the attB docking site of a genetically engineered cytoadherent parasite line. Using this system, we define sequence requirements for PfEMP1 surface display and demonstrate that two PfEMP1 proteins can be simultaneously expressed at the infected RBC surface.
Results

Insertion of the attB site into the Type 3 var gene by homologous recombination
To develop a system to express recombinant, full-length PfEMP1, we first engineered an attB site into the P. falciparum A4 parasite line, a highly cytoadherent subclone of IT4/25/5 (Roberts et al., 1992) . As the recipient var gene, we chose the type 3 IT4var3 sequence because it is the smallest known PfEMP1 protein (Gardner et al., 2002; Kraemer et al., 2007) . We designed the plasmid pDCattB-var3(HA) ( Table S1 ) to enable homologous recombination and single site cross-over into its first exon (Fig. 1A) . This plasmid harboured an attB site just upstream of the IT4var3 start codon, which would serve as the docking site for incoming attP containing plasmids and permit site-specific integration. Our initial intention was to introduce an attB site and a hemagglutinin (HA) epitope into the native IT4var3 gene, and use a constitutive ef-1a promoter to drive gene expression. This would allow us to test whether a small atypical PfEMP1 protein encoded sufficient information for RBC surface transport. This strategy would also enable expression of var genes with selected PfEMP1 adhesion domains, independent of var gene activation mechanisms, via a second round of integrase-mediated attB ¥ attP recombination.
We electroporated the pDC-attB-var3(HA) plasmid into A4 parasites and applied the antimalarial antifolate WR99210 to select for a recombinant parasite line expressing the plasmid-borne human dihydrofolate reductase (dhfr) selectable marker (Fidock et al., 1998) . Following a period of episomal plasmid replication, we observed integration into the IT4var3 exon 1 sequence in these parasites by PCR screens that specifically detected the upstream and downstream junctions of homologous recombination and single-site cross-over (Fig. 1B) . This line was named A4 attB . Evidence that the plasmid had integrated was provided by the detection of a PCR product that amplified over the cross-over site of the transfection plasmid, and the lack of a product for the wild-type (WT) locus (Fig. 1B) . By PCR, we also detected the presence of an HA tag in the IT4var3 exon1, both upstream and downstream of the integration site (Fig. 1B) . This likely reflects further rearrangements that must have occurred after the initial single-site cross-over event, in which the original WT exon 1 was either looped out during in situ DNA recombination, or corrected via DNA repair mechanisms to incorporate the HA epitope. Southern blot analysis of genomic or plasmid DNA digested with BglII and hybridized with an IT4var3 exon 1 probe showed an~16 kb band in A4 parasites, and an additional band of 8.4 kb in A4 attB parasites, as predicted following plasmid integration into this exon (Fig. 1C) . Hybridization, with the exon 1 probe, of DNA digested with ZraI plus ClaI yielded a 9.5 kb band for the A4 parental line and a 4.3 kb band for the digested plasmid. The A4 attB line yielded a 2.9 kb band, corresponding to the 3′ integration site, and a more intense 4.3 kb band indicating that the plasmid had integrated as a concatemeric array (indicated in Fig. 1A by curved brackets) . The resulting locus thus consisted of multiple truncated IT4var3 genes, each with a preceding attB site, and one full-length IT4var3 gene under the control of the P. berghei ef-1a promoter and harbouring an attB site located between the promoter and the IT4var3 start codon. As expected, the IT4var3 transcript could be detected by reverse transcriptase PCR following plasmid integration, independently of the mutually exclusive control of var gene expression (data not shown). However, Western blot analysis using monoclonal antibodies directed against the HA epitope failed to detect recombinant protein (data not shown), possibly because of interference of the attB site with the initiation of translation. Therefore, to study PfEMP1 function, we adapted our original strategy and generated attP-containing constructs carrying a second promoter (selected from the highly expressed hrp3 gene, see below) to drive the expression of mini-var genes after plasmid integration into the attB sites.
The
A4 attB locus is highly amenable to integrase-mediated recombination
To assess attB ¥ attP recombination in the A4 attB parasite line, we co-transfected the integrase-expressing plasmid pINT with pLN-GFP, a GFP-expressing attP plasmid shown previously to integrate into the Dd2 attB parasite line . Parasites were selected with 100 mg ml -1 of neomycin (NEO) (to select for pINT) and varying concentrations of blasticidin (BSD) (for pLN-GFP), ranging from 0 to 2.0 mg ml -1
. On day 34 post-transfection, we confirmed integration by PCR ( Fig. S1A and B) . All lines were positive for integration and negative for unrecombined attP. Parasites selected on NEO alone displayed no growth delay when later selected on BSD (data not shown) and no significant difference in the numbers of GFP-expressing cells were detected by live cell fluorescence (Fig. S1C ), indicating that successful attB ¥ attP integration was not dependent on drug selection of the attP plasmid.
NTS segment 19-25 amino acids after the protein N-terminus (Marti et al., 2005) , or about two-thirds into the DBL1 domain (Hiller et al., 2004) . To investigate specific PfEMP1 requirements for protein trafficking, we designed mini-var constructs that were expressed during the ring stages by an hrp3 promoter, and contained both a V5 epitope and a GFP protein tag to facilitate detection. A listing of these plasmid constructs is provided in Fig. 2 and Table S1 . These included one mini-var construct (p-attP-hrp3-NTS-V5-GFP) based on the first 197 amino acids (referred to herein as NTS) of IT4VAR3 PfEMP1 containing the NTS with the first predicted PEXEL-like attB locus after homologous recombination and single-site cross-over (figure not drawn to scale). This shows the positions of PCR primers, enzyme digestion sites (C, ClaI; B, BglII; Z, ZraI), fragment sizes, and the IT4var3 probe hybridization sites (black bars). Concatameric plasmid integration is indicated by curved brackets, where n Ն 1. Grey shading indicates the two-exon structure of the IT4var3-coding sequence. The human dhfr selectable marker cassette, elongation factor-1a promoter (ef-1a 5Ј), the integrated attB site, and the HA epitope tag are also indicated. B. PCR analysis of the IT4var3 locus after homologous recombination and single-site cross-over. The following primers were used: 1093 and 1096 to detect the 3.1 kb WT IT4var3 locus; 1093 and M13R to detect the 3.0 kb recombinant upstream junction; 1091 and 1096 to detect the 3.1 kb recombinant downstream junction; 1091 and M13R to detect plasmid (also faintly present in the A4 attB lane); 1093 and 1094 to detect the 0.7 kb recombinant upstream HA epitope tag; and 1095 and 1096 to detect the 2.3 kb recombinant downstream HA tag. 'Plasmid' refers to pDC-attB-var3(HA). C. Southern blot analysis of the A4 attB parasite line using an exon 1 IT4var3 probe. BglII digestion of genomic DNA from the A4 parental line liberated nearly the entire IT4var3 gene as a~16 kb fragment. Digestion of the A4 attB parasite with BglII liberated full-length (8.4 kb) pDC-attB-var3(HA) plasmids in addition to the~16kb fragment. The presence of the HA epitope in the up-and downstream loci was confirmed by digestion with ZraI plus ClaI, which liberated 4.3 kb (upstream) and 2.9 kb (downstream) fragments in A4 attB . Images were generated from the same exposure but intervening lanes were cropped for spacing.
motif and the first half of the DBL1 domain, but not the second predicted PEXEL-like motif. The corresponding protein product is designated NTS-V5-GFP in Fig. 2A . We also generated two constructs harbouring this NTS sequence fused to the IT4VAR3 TM domain and cytoplasmic tail or acidic terminal sequence (ATS), with GFP fused downstream or upstream of the TM domain (to attempt to locate GFP in the intracellular or extracellular space, respectively; protein products designated NTS-V5-TM-ATS-GFP and NTS-V5-GFP-TM-ATS; Fig. 2A ). Finally, we generated larger miniPfEMP1 proteins incorporating the semi-conserved head structures of either a Group B PfEMP1 variant (A4var, amino acids 1-846 containing the DBL1a and CIDR1g domains) (Smith et al., 1998; 2000a) or a Group A PfEMP1 variant (R29var, amino acids 1-787 containing the DBL1a1 and CIDR1a1 domains) (Rowe et al., 1997) . These larger transgene products possessed both predicted PEXEL-like motifs ( Fig. 2A) . These constructs all encoded the IT4VAR3 TM domain and cytoplasmic tail (amino acids 849-1324), with the GFP tag placed either just prior to the TM or following the ATS domain (products designated A4var-V5-TM-ATS-GFP, R29var-V5-TM-ATS-GFP and R29var-V5-GFP-TM-ATS; Fig. 2A ).
Plasmid constructs were transfected in combination with pINT into the A4 attB parasite line as described above, and recombined parasite lines were obtained 14-23 days post-transfection following selection with 100 mg ml A. Schematic of a native PfEMP1 and miniPfEMP1 proteins depicting their predicted organization and topology. The top row shows a generic PfEMP1 with its protein head structure (composed of NTS, DBL1 and CIDR1 head domains, a variable number of internal domains, a TM and an ATS). The Type 3 var encodes the smallest PfEMP1 protein and lacks a CIDR1 domain (Gardner et al., 2002; Kraemer et al., 2007) . The red cell membrane is indicated by two black bars, with predicted extracellular sequence to the left. The miniPfEMP1 recombinant molecule NTS-V5-GFP is depicted as residing within the intracellular space (note that the parasite vacuolar and plasma membranes have been omitted for clarity). V5, V5 epitope. B. Schematic diagram depicting Bxb1 integrase-mediated recombination of a mini-var transgene into the attB-tagged IT4var3 locus. Coding regions are indicated by their grey shading. This schematic also indicates the probe hybridization site (black bars), the human dhfr cassette, the blasticidin resistance marker (bsd cassette), ef-1a 5′ UTR, hrp3 5′ UTR, hsp86 3′ UTR, the attP site, the attB element, the neomycin resistance cassette (neo cassette), the Bxb1 integrase cassette (Integrase cassette) and the HA tag. This schematic also shows the positions of primers used to verify integration.
(to select for the attP plasmid). A schematic of the attB ¥ attP recombination event, leading to expression of the mini-var genes under control of the strong hrp3 promoter (which is not subject to allelic exclusion), is presented in Fig. 2B . For ease of interpretation, the resulting recombinant lines were assigned the same name as the protein products represented schematically in Fig. 2A , and were consistent with the naming of the corresponding transfection constructs listed in Table S1 . Integration was confirmed by PCR amplification over the attL and attR junctions, which represent the chimeric products of attB ¥ attP integrase-mediated recombination (Fig. 3A) . Unrecombined attP and attB sites could also be detected in several of the parasite lines. This indicated that integration events did not occur in all of the multiple attB sites present and that the attP plasmid had likely concatemerized prior to integration, because these PCR products were also detected in the absence of BSD selection on the attP plasmid (arguing against the presence of episomal plasmid).
To investigate protein expression, trophozoite extracts were prepared from parasite cultures harvested by gelatin flotation. MiniPfEMP1 proteins were detected by Western blot using anti-GFP antibodies. In each case, the anti-GFP antibodies detected a dominant band of the correct predicted size (Figs 2A and 3B ). Antibodies specific to the ER-Golgi marker BiP (Kumar et al., 1991) were used as a control to ensure protein was loaded in all lanes, including those negative for GFP staining (Fig. 3B) .
Patterns of miniPfEMP1 export into and within the infected erythrocyte
To analyse miniPfEMP1 transport, BODIPY lipid and DAPI DNA staining were employed to distinguish between the parasite and RBC compartments by fluorescence microscopy of trophozoite-infected RBCs (Tamez et al., 2008) . BODIPY stained several lipid-containing structures including the RBC membrane, lipid structures in the RBC cytoplasm and the parasite membrane/PVM. The presence of DNA staining marked the intracellular parasite. In combination with these staining methods, GFP fluorescence allowed us to identify several patterns of miniPfEMP1 trafficking: retention within the parasite ('Parasite'), retention at the PVM ('PVM associated'), export into the RBC cytoplasm ('RBC'), or localization at or near the RBC membrane ('RBC membrane') ( Fig. 4A ). The percentage of each pattern was determined by analysing at least 50 individual infected RBCs from each line (Fig. 4B ). As predicted by the absence of an N-terminal hydrophobic sequence, the construct containing only the NTS was insufficient to mediate export to the RBC, with 'export' defined as fluorescence within the RBC cytoplasm or at the RBC membrane ('RBC' and 'RBC membrane').
Ninety-six per cent of infected RBCs retained the NTS-V5-GFP miniPfEMP1 within the parasite (Fig. 4B) .
In contrast, the placement of the TM domain and the cytosolic tail downstream of the NTS, in the lines NTS-V5-TM-ATS-GFP and NTS-V5-GFP-TM-ATS, increased export to greater than 80% of observed cases. Furthermore, the miniPfEMP1 transgenes expressed in the A4var-V5-TM-ATS-GFP and R29var-V5-GFP-TM-ATS lines were exported in 78% and 93% of observed cases respectively (Fig. 4B) .
For most constructs, placement of the GFP tag within the predicted extracellular or intracellular portion of the A. PCR analysis of transfected lines was performed using the following primers: 1091 and 1094 to detect unrecombined attB sites; 1091 and 1090 to amplify the 5′ attL junction; 594 and 1094 to amplify the 3′ attR junction; and 594 and 1090 to detect unrecombined plasmid or plasmid that integrated as a concatemer. PCR product sizes are indicated. 'P' indicates the attP plasmid used in the generation of each line. B. Western blot of protein extracts from transgenic parasite lines expressing miniPfEMP1s. These extracts were probed with antibodies to GFP (top panel), or BiP (used as a loading control and shown on the bottom panel). The expected miniPfEMP1 product sizes are listed to the left of panel.
miniPfEMP1 polypeptide did not significantly modify export efficiency beyond the PVM. However, the R29varV5-TM-ATS-GFP construct was less well exported than other constructs with~46% of the infected RBC exhibiting some protein retention at the parasite membrane and/or PVM (Fig. 4B ). Retained R29var-V5-TM-ATS-GFP proteins were found in discrete foci in the membrane surrounding the parasite (Fig. 4A) , in a pattern reminiscent of the one reported for the protein translocon machinery (de Koning-Ward et al., 2009) . In the majority of cases, export of miniPfEMP1 proteins beyond the PVM led to localization near or at the RBC membrane. In addition, all five miniPfEMP1 constructs that were exported to the RBC cytoplasm gave a punctate staining pattern. In virtually all observed cases, the miniPfEMP1 proteins that were localized within the RBC cytoplasm appeared to be associated with BODIPY-labelled structures (Fig. 5 ). These might correspond to Maurer's clefts or other vesicular structures in the RBC cytoplasm.
MiniPfEMP1 proteins containing a complete head structure are exposed at the RBC surface in the correct orientation
To examine whether miniPfEMP1 proteins were transported to the RBC surface in the proper membrane orientation, we performed flow cytometric analysis on live trophozoite-stage infected RBCs using antibodies directed against either the V5 epitope or GFP tags (Fig. 6A ). Whereas miniPfEMP1 proteins containing the NTS in combination with the TM region and cytoplasmic tail, namely NTS-V5-TM-ATS-GFP and NTS-V5-GFP-TM-ATS, were efficiently exported to the RBC and localized near the RBC membrane ( Fig. 5 ), we were unable to detect recombinant PfEMP1 surface staining in either line (Fig. 6A , left panels). This suggests a possible defect in the translocation and presentation of these miniPfEMP1 proteins on the RBC surface. In contrast, all of the miniPfEMP1 proteins that encoded complete semiconserved head structures with full-length DBL and CIDR domains (namely A4var-V5-TM-ATS-GFP, R29var-V5-TM-ATS-GFP and R29var-V5-GFP-TM-ATS; Fig. 6A , right panels) were surface positive with anti-V5 monoclonal antibody. Moreover, anti-GFP polyclonal sera reacted with infected RBC in which the GFP label was positioned in the extracellular region of the miniPfEMP1 protein (R29var-V5-GFP-TM-ATS) and not within the luminal side of the RBC membrane (R29var-V5-TM-ATS-GFP) (Fig. 6A) .
Surface exposure was further confirmed using specific antisera to the A4var CIDR1 or the R29var DBL1 domains and controlled by non-transfected parasite lines expressing native A4var or R29var PfEMP1 proteins. We detected The first column of images represents GFP fluorescence, the second column BODIPY lipid staining, the third column DAPI staining of parasite DNA and the fourth column an overlay of the three images. The NTS-V5-GFP construct was confined to the parasite and other miniPfEMP1 constructs were typically exported to the RBC cytoplasm. Exported proteins had a punctate staining pattern and GFP signal generally colocalized with BODIPY-labelled structures in the RBC cytoplasm (white arrowheads). similar levels of anti-A4var CIDR1 antibody binding at the RBC surface of lines expressing native A4var PfEMP1 and the A4var-V5-TM-ATS-GFP miniPfEMP1 fusion protein (Fig. 6B, top panels) . Similarly, anti-R29var DBL1 antibodies labelled the surface of infected RBCs expressing native R29var or recombinant R29var-V5-TM-ATS-GFP and R29var-V5-GFP-TM-ATS (Fig. 6B , bottom panels). Antibody binding was specific, as shown by the lack of cross-reactivity between parasite lines expressing either A4var or R29var PfEMP1 domains. In these three parasite lines, the complete population of infected RBCs displayed miniPfEMP1 at the surface, including the R29var-V5-TM-ATS-GFP line that showed partial retention at the PVM. Thus, miniPfEMP1 proteins containing semi-conserved head structures possessed all the necessary signals for transport and integration in the correct membrane orientation at the RBC surface.
To investigate miniPfEMP1 localization at the ultrastructural level, immuno-electron microscopy (immuno-EM) was performed with anti-GFP antibodies. With the NTS-V5-TM-ATS-GFP line, we observed immunogold particles in the RBC cytoplasm, with evidence of association with electron dense material (Fig. 7A) . In this line, we also observed particles in the parasite cytoplasm, in some cases located adjacent to the parasite plasma membrane (Fig. 7B) . Consistent with the flow cytometry data, surface labelling of infected RBCs was never observed in 40 images taken of this line, although the anti-GFP antibody reacted with this protein in the RBC cytoplasm (Fig. 7A) . Electron tomogram studies with the R29var-V5-TM-ATS-GFP line confirmed export of this miniPfEMP1 fusion protein into the RBC cytoplasm (Movie S1).
Immuno-EM studies were also performed with the R29var-V5-GFP-TM-ATS line that efficiently exported PfEMP1 into the host RBC ( Fig. 7C-H) . These identified miniPfEMP1 proteins in the RBC cytoplasm (Fig. 7C) , and at sites associated with or adjacent to knob-like structures in the RBC membrane ( Fig. 7D-H) . Some parasites also showed evidence of physical proximity to Maurer's clefts (Fig. 7H) . These patterns are reminiscent of images observed with a previously reported KAHRP-PfEMP1 chimera (Knuepfer et al., 2005) . Taken together, our studies suggest that miniPfEMP1 proteins encoding the PfEMP1 semi-conserved head structure and cytoplasmic tail were capable of being transported to the RBC surface where they were often located at or near parasite-induced knob structures.
MiniPfEMP1 proteins can be surface exposed simultaneously with endogenous PfEMP1
From our flow cytometry data, we observed that whereas the A4var miniPfEMP1 protein was expressed at approximately the same level as native A4var PfEMP1 in nontransfected parasites, the R29var miniPfEMP1 proteins were expressed at slightly lower levels than their native counterparts (Fig. 6B) . Because miniPfEMP1 proteins are expressed independent of var gene regulatory mechanisms, this raises the possibility of competition between miniPfEMP1 and native PfEMP1 proteins for their association with knob structures or surface display. To determine whether two different PfEMP1 variants can be simultaneously displayed at the RBC surface, parasite lines expressing the A4var and R29var miniPfEMP1 proteins were selected on the placental adhesion receptor CSA to enrich for a specific PfEMP1 variant (Salanti et al., 2003) . After six rounds of panning on CSA, all of the parasite lines had switched to VAR2CSA as the endogenous PfEMP1 protein, as evidenced by anti-VAR2CSA antibody labelling. Notably, these also retained expression of miniPfEMP1 protein on the infected RBC surface (Fig. 8) , demonstrating that a single infected RBC can express two different PfEMP1 proteins at the RBC surface. We note that levels of endogenous VAR2CSA PfEMP1 were comparable between the A4var and the two R29var lines, despite differences in the degrees to which they exported their miniPfEMP1 out to the RBC cytoplasm (Fig. 4B) .
Having selected for VAR2CSA as the endogenous PfEMP1 variant, we also investigated whether miniPfEMP1 proteins were able to confer new binding properties on infected RBCs. VAR2CSA is known to bind to the host receptor CSA, but does not mediate infected erythrocyte rosetting or CD36 binding. Our studies were predicated on earlier reports that these binding properties reside within the R29var and A4var head structures respectively (Rowe et al., 1997; Smith et al., 1998) . As   Fig. 7 . Ultrastructural analysis of miniPfEMP1 transport. The NTS-V5-TM-ATS-GFP or R29var-V5-GFP-TM-ATS parasite lines were analysed by immunogold EM with anti-GFP antibodies. A. NTS-V5-TM-ATS-GFP, immunogold particles were observed in association with an electron dense structure in the RBC cytoplasm. B. NTS-V5-TM-ATS-GFP localized close to the parasite plasma membrane. C. R29var-V5-GFP-TM-ATS immunogold particles were observed close to the PVM. D-H. R29varV5-GFP-TM-ATS parasites were labelled with anti-GFP, revealing miniPfEMP1 fusion proteins at the RBC surface at or near knob structures, as well as near a Maurer's cleft in the RBC cytoplasm (H). Anti-GFP immunogold label is found at the RBC surface or in close proximity to Maurer's clefts (H). Labelling with 10 nm immunogold was performed after cryosectioning (A to F and H) or prior to fixation with 2% glutaraldehyde (G). White arrowheads, Maurer's clefts; black arrowheads, surface knobs of infected RBCs. Scale bars 200 nm, p parasite, rbc red blood cell cytoplasm.
expected, all of the panned lines bound to CSA above background (Fig. S2) . However, we could not detect binding of the A4var miniPfEMP1 to CD36, and infected RBCs expressing the R29var miniPfEMP1 were insufficient to mediate rosetting (data not shown). As the larger VAR2CSA protein may have sterically hindered binding, we also tried limited protease digestion of infected erythrocytes to selectively remove the native PfEMP1. The miniPfEMP1 proteins were found to be highly sensitive to low trypsin concentrations, ranging from 0.1 to 1.0 mg ml -1 (Fig. S3) , supporting their surface localization. However, we were unable to define protease conditions that would digest the VAR2CSA protein and leave the miniPfEMP1 protein intact (Fig. S3) . Thus, miniPfEMP1 proteins containing the semi-conserved head structure possessed sufficient structural integrity for surface transport and presentation, but not for binding or rosetting activity, suggesting that additional domains might be required to mediate adhesion.
Discussion
Plasmodium falciparum causes infected RBC sequestration in peripheral blood vessels through the exportation of PfEMP1 virulence factors to the host cell surface. In this study, we provide the first model system to study the trafficking of a PfEMP1 protein to the RBC surface, by using the Bxb1 integrase system to rapidly integrate minivar constructs into the cytoadherent A4 parasite line. We demonstrate that this system of transgene expression is highly efficient, and does not require drug selection on the attP plasmid. Integration is stable, because attB ¥ attP recombination yields the attL and attR sites that are resistant to excision by Bxb1 integrase. This should permit integration of larger full-length PfEMP1 transgenes through the removal of the blasticidin S-deaminase (bsd) cassette, thereby allowing the cloning and propagation of larger transgenes with smaller plasmid backbones.
Two signals are typically required to allow protein export to the RBC, namely an N-terminal hydrophobic sequence for entry into the parasite ER, and a PEXEL/ VTS motif for translocation across the PVM (Hiller et al., 2004; Marti et al., 2004; de Koning-Ward et al., 2009) . However, PfEMP1 proteins differ from most exported proteins because they lack a defined N-terminal signal sequence, with the PfEMP1 TM domain appearing to direct the protein to the parasite ER instead (Knuepfer et al., 2005) . Additionally, two different non-canonical PEXEL-like motifs have been proposed in PfEMP1 proteins. Both motifs were shown to mediate export to the host cell when combined with the TM and ATS domains (Hiller et al., 2004; Marti et al., 2004) . However, while the first is located within the NTS domain, the second motif is found in all DBL domains, including several EBL genes that localize to microneme organelles within the parasite; therefore its function has been called into question (Templeton and Deitsch, 2005) . In this study, we show that the first motif is sufficient for export of miniPfEMP1 proteins into the RBC, but that additional information in the protein head structure is required for RBC surface display. This presumably reflects the existence of additional control mechanisms that operate post-PVM export.
Our study reveals that the PfEMP1 semi-conserved head structure in cooperation with the TM region and ATS domain encodes sufficient information for RBC surface transport of both a Group A (R29var) and a Group B (A4var) miniPfEMP1 protein. These miniPfEMP1 proteins associate with knob-like protrusions at the infected RBC surface in the correct membrane orientation. This is notable because the head structure is the most conserved extracellular region between PfEMP1 proteins (Smith et al., 2000b) and was previously known to be important only for host receptor binding (Baruch et al., 1997; Rowe et al., 1997; Chen et al., 1998; Robinson et al., 2003) . Our results provide compelling evidence to suggest that this region is also under selection for PfEMP1 protein translocation to the cell surface.
In contrast, miniPfEMP1 proteins with truncated head structures were exported to the RBC cytoplasm but could not be detected at the host cell surface. Several explanations are possible, including that a truncated head structure might not fold properly or be unable to interact with an accessory protein(s) required for the final stage of protein transport from Maurer's clefts to the infected RBC surface. Indeed, a number of accessory proteins required for PfEMP1 transport have been described, including those that are located within the Maurer's cleft lumen or that are associated with Maurer's clefts in the RBC cytoplasm (Cooke et al., 2006; Maier et al., 2006; 2007) . Another possibility would be a requirement for an additional signal in the PfEMP1 head structure that is necessary for the final stages of transport. While a prior study observed transport to the RBC surface with a fusion protein of the first 120 amino acids of KAHRP (containing a PEXEL motif and an N-terminal hydrophobic sequence) that were coupled with PfEMP1 TM and ATS domains (Knuepfer et al., 2005) , those findings do not exclude a role for additional features within the PfEMP1 head structure. The fact that there exist different final destinations for P. falciparum proteins that are exported to the infected RBC might even argue for the necessity of additional signals in these proteins, especially if the Maurer's cleft serves as a sorting point.
This analysis also shows the absence of any mechanistic barriers to having two different PfEMP1 proteins (mini and endogenous) expressed at the RBC surface. Such a scenario could occur in multiply infected RBC, potentially modifying their binding properties and endothelial binding tropism. Previous work had suggested that infected RBC might gain adhesion properties upon disruption of var gene silencing mechanisms (Tonkin et al., 2009) . However, the current report would appear to be the first to directly show simultaneous expression of two PfEMP1 variants at the RBC surface by antibody labelling.
Interestingly, we did not observe adhesion of the A4var miniPfEMP1 to CD36, an initially unexpected result given that CD36 binding was previously mapped in vitro to the A4var CIDR1 domain encoded within our transgene construct (Smith et al., 1998) . Nor did we find the R29var miniPfEMP1 to be sufficient to mediate infected RBC rosetting, even though the DBL1 domain, present within this miniPfEMP1, binds complement receptor 1 on RBCs when expressed as a fusion protein from heterologous cells (Rowe et al., 1997) . Neither of those former studies on adhesive properties of individual domains, however, addressed binding activity at the surface of infected RBCs, and conceivably the assembly of PfEMP1 proteins within the knob structure might have influenced miniPfEMP1 binding properties. To assess whether binding regions in miniPfEMP1 proteins could have been buried or rendered sterically inaccessible, perhaps hidden by the larger co-expressed VAR2CSA protein, we also attempted partial protease digestion. However, we were unable to define protease conditions that would cleave the VAR2CSA protein while leaving miniPfEMP1 intact, thus making it impossible to test for steric hindrance. We note that most PfEMP1 proteins have four or more extracellular domains, and it is possible that internal domains may be required to maintain the head structure at a proper distance from the RBC membrane to enable CIDR1-CD36 interactions.
Another interpretation of our data is that single domains were insufficient to mediate binding because they do not reconstitute the structural requirements for adhesion. This would infer that multiple domains would be required for binding. This interpretation is consistent with two recent reports showing that recombinant VAR2CSA protein expressing the complete extracellular domain (containing six DBL domains) had at least 1000-fold greater affinity for binding CSA than that displayed by individual domains, implying that multiple binding domains may contribute to higher binding affinity or that ligand binding required higher-order structure of multiple domains involving interdomain interactions (Khunrae et al., 2010; Srivastava et al., 2010) .
With the expression of larger miniPfEMP1 proteins using the Bxb1 integrase system, it should prove possible in future studies to identify the minimal requirements for infected RBC binding and investigate cooperation between domains as they pertain to binding, in the native context at the RBC cell surface. This would represent a significant advance from the limitations of the current technology, based on recombinant PfEMP1 domain expression in heterologous eukaryotic cells. This system also provides an in vivo tool for the characterization of molecular interactions between the PfEMP1 cytoplasmic tail and knob structures. In conclusion, the miniPfEMP1 system developed herein provides a useful system to analyse transport of this virulence determinant to the RBC surface and suggests the PfEMP1 head structure is under selection for both binding and protein transport.
Experimental procedures
Plasmid construction
Plasmids pINT, pLN-GFP and pCBD-P were described previously . The construction of transfection and intermediary shuttle plasmids is detailed in the Supplementary Experimental Procedures. Table S1 lists all plasmids created during this study. This includes pDC-attB-var3(HA), which was generated by introducing an attB element upstream of the HA-tagged IT4var3 exon 1 and inserting this cassette into a plasmid expressing the human dhfr selectable marker. The attPcontaining plasmids were generated from pDC-var3(attB-HA) by replacing the truncated IT4var3 open reading frame with mini-var transgene elements, and exchanging the human dhfr cassette with a bsd cassette. All fragments were PCR amplified from genomic DNA of the P. falciparum IT4/25/5 clone A4 (Roberts et al., 1992) , unless otherwise noted. Plasmids were verified by sequencing prior to transfection. Sequences of primers used for cloning or PCR analysis are listed in Table S2 . Representative mini-var plasmid maps are presented in Fig. S4 .
Parasite propagation and transfections
All parasite lines described in this study were generated from the IT4/25/5 clone A4 (Roberts et al., 1992) , and were cultured under standard conditions (Trager and Jensen, 1976) in RPMI-1640 medium supplemented with 10% pooled heat-inactivated AB + serum (Interstate Blood Bank, Memphis, TN), 0.5% w/v Albumax II (Invitrogen, Carlsbad, CA) and Lymphoprep (Axis-Shield)-purified human RBCs at 3-5% hematocrit. Cultures were frequently subjected to gelatin flotation (Waterkeyn et al., 2001 ) to maintain selection for cytoadherence. The A4 attB parasite line was propagated in the presence of 0.4 nM WR99210 (Jacobus Pharmaceuticals, Princeton, NJ). MiniPfEMP1 lines were cultured in the presence of 1.0-2.5 mg ml -1 blasticidin hydrochloride (BSD) (Invitrogen).
Transfections to incorporate the attB element were performed using ring-stage parasites at approximately 5% parasitemia. Cells were electroporated with 100 mg of plasmid in 0.4 cm cuvettes using low voltage (0.31 kV) and high capacitance (950 mF) (Fidock and Wellems, 1997) , and aliquoted to triplicate 2 ml wells. Transfected lines were cloned by limiting dilution on day 104 post-transfection. Site-specific recombination of attP plasmids was accomplished by co-transfecting A4 attB parasites with 50 mg of attP plasmid and 50 mg of pINT plasmid as described above. To select for transfected parasites, 100 mg ml -1 of G418 sulfate (NEO) (Cellgro) Ϯ 1.0 mg ml -1 BSD was added on day 2 post-transfection. Integration events were verified by sequence-specific PCR screening and Southern blot analysis, as documented below.
DNA analysis
Plasmodium falciparum genomic DNA was obtained from trophozoite-stage-infected RBCs by saponin lysis and purified using DNeasy Tissue Kits (Qiagen). Integration of plasmid pDCattB-var3(HA) was detected with primers 1093 to the 5′ untranslated region (UTR) and 1096 to exon 2 of the IT4var3 locus, primers 1094 and 1095 to the HA epitope tag, primer 1091 to the ef-1a 5′UTR, and primer M13R to the plasmid backbone of pDClink (described in Supplementary Experimental Procedures and Table S1 ). To detect integrase-mediated attB ¥ attP sitespecific integration of mini-var transgenes, the attL junction was detected using primers 1091 and 1090 (to the hrp3 5′ untranslated region of pLN-GFP), the attR junction using primers 594 (specific to bsd cassette) and 1094, and plasmid using primers 594 and 1090 (primer locations depicted in Fig. 2A ). For Southern blot analysis, 1.5 mg of DNA was digested with enzyme(s) as indicated, electrophoresed on a 0.8% polyacrylamide gel, and transferred onto nylon membranes overnight. A [ 32 P]-radiolabelled probe [made from a ZraI-BstBI fragment isolated from plasmid pDC-attB-var3(HA)] was hybridized to the membranes overnight at 56°C.
Antibody production
To produce antibodies specific to R29var-encoded PfEMP1, we produced the recombinant domain encompassing residues 1-481 as a soluble protein in Escherichia coli using a baculovirus codon-adjusted version (to decrease the A-T richness of the sequence) and the pMAL-c2X (New England Biolabs) vector. This expressed domain was cleaved from the maltose-binding protein fusion by treatment with the protease Factor Xa. Purified R29var protein was used to immunize BALB/c mice (10 mg per injection in Freund's complete adjuvant for the first injection and Freund's incomplete adjuvant for two subsequent boosts at 3 week intervals). A pool of sera was obtained by mixing serum from five animals bled 8 days after the final immunization (ViganWomas et al. in preparation) . A4var antibodies were produced by immunizing rabbits with a plasmid DNA vector (VR1051) expressing the A4CIDR1 region (residues 402-846), as described previously (Avril et al., 2008) .
Western blotting
Western blotting was performed on SDS-detergent extracts of mature infected cells harvested after MACS cell sorting (Miltenyi biotec). Cell extracts were electrophoresed on a 6% SDS-PAGE gel and transferred to polyvinylidene difluoride membranes.
Primary incubation was performed with mouse anti-GFP monoclonal antibodies (Clontech), followed by secondary incubation with horseradish peroxidase-conjugated donkey anti-rabbit IgG (Amersham Biosciences). Bands were visualized by chemiluminescence using the ECL Western blot analysis system (Amersham Biosciences). The blot was stripped and reprobed with anti-BiP antibodies (Kumar et al., 1991) followed by secondary antibody detection with anti-rabbit IgG as described above.
Flow cytometry analysis
Trophozoite stage-infected RBCs were incubated for 1 h at room temperature with a variety of primary antibodies: mouse anti-V5 (Invitrogen) (diluted 1:50), rabbit anti-GFP (Millipore) (1:50), rabbit anti-A4var CIDR1 (1:10), rabbit anti-VAR2CSA DBL1 (1:10) (Avril et al., 2008) 
Immunogold electron microscopy
Immuno-EM was performed according to methodology described in Tokuyasu (1973) . Cells were purified over a SuperMACS column of magnetic beads, fixed in 80 mM phosphate buffer containing 4% paraformaldehyde and 0.1% glutaraldehyde, embedded in 2% gelatin, and cryo-preserved in 2.3 M sucrose. Gelatin blocks were frozen in liquid nitrogen and cut in an ultramicrotome (Leica) at -110°C to achieve 90 nm thin sections. Immunolabelling was done in 0.8% BSA and 1% fish gelatin in PBS with rabbit polyclonal anti-GFP primary antibodies (diluted 1:30; Invitrogen) and 10 nm immunogold-coupled antirabbit IgG secondary antibodies (diluted 1:40; Electron Microscopy Sciences). For immunolabelling of cells prior to fixation, anti-GFP labelling was done in 2% BSA in PBS followed by fixation with 2% glutaraldehyde in 80 mM phosphate buffer. After immunolabelling, the sections were stained at 4°C in an aqueous solution of 0.3% uranyl acetate and 1.8% methylcellulose.
Images were taken at room temperature in a Tecnai F20 FEG at 200keV at 14 500 ¥ magnification and processed with ImageJ (NIH). Tilt series for tomographic reconstruction were obtained at room temperature at 11 500 ¥ magnification. The sample was rotatedϮ 60°in maximally 2°increments following the Saxton scheme . The final tomograms were calculated with the 'protomo' software package using a marker-free alignment and weighted backprojection. The Movie S1, which shows tomographic reconstruction of R29var-V5-TM-ATS-GFP parasites stained with anti-GFP antibodies, can be viewed with H.264 capable movie players, including the opensource platform-independent 'vlc player' (http://www.videolan. org/videolan).
Panning of infected RBCs on CSA and infected RBC binding assays
A sterile culture flask was coated with 0.1 mg ml -1 CSA overnight at 4°C and blocked with 2% BSA in PBS for 1 h at 37°C. Infected RBCs were enriched by gelatin flotation and incubated in the coated flask for 2 h. Non-adherent RBCs were removed by gentle washing with warm culture medium. Adherent (panned) RBCs were washed off with medium and cultured. Infected RBCs were panned a total of six times on CSA with periods of parasite replication between rounds of panning. Assessments of infected RBC binding to CD36 or CSA or infected rosetting were performed according to standard methodologies [ (Rowe et al., 1997; Avril et al., 2008) ; see Supplementary Experimental Procedures for further details].
Live cell imaging
Infected erythrocytes at the trophozoite stage were enriched by gelatin flotation. Cells were incubated with BODIPY-TR-ceramide (diluted 1:500; Invitrogen) in culture medium for 1 h at 37°C, followed by incubation with 1 mg ml -1 DAPI in PBS for 15 min. Cells were subsequently washed with PBS. A drop of cell suspension in PBS was then put on a slide, covered by a coverslip and pictures were taken on a Nikon Eclipse E600 microscope. Picture analyses and overlays were performed using Metamorph (Molecular Devices). 
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Supplementary Experimental Procedures
Plasmid construction
We prepared the pDC-attB-var3(HA) plasmid (Supplementary Table S1 ) in several steps. First, the transgene acceptor cassette from the plasmid pDC (Fidock et al., 2000) was removed using the enzyme SphI, and replaced with an annealed multi-restriction site oligonucleotide linker (made from top strand oligomer 354 and bottom strand oligomer 355; see a listing of this and all others primers in Table S2 ) to generate the plasmid pDClink (listed along with other plasmids in Table S1 ). This transfection plasmid expressed the human dihydrofolate reductase (hdhfr) selectable marker under the control of the 0.6 kb Plasmodium chabaudi dihydrofolate reductase -thymidylate synthase (PcDT) 5' untranslated region (UTR) and a 0.9 kb P. berghei DT 3'UTR. The P. berghei elongation factor-1alpha (ef-1α) 5' UTR sequence was obtained from a clone kindly provided by Dr.
Andy Waters (University of Glasgow, Scotland). The first 900 codons of the var gene IT4var3 were amplified in a two-step reaction, whereby the hemagglutinin (HA) epitope YPYDVPDYA (sequence 5'-TACCCATACGACGTCCCAGACTACGCT) was incorporated between residues 204 and 212 in plasmid pDCattB-var3(HA), as follows. In the first step of the reaction, a 5' fragment was amplified with the primers SK5 and SK6 and a 3' fragment with SK7 and SK8. These two PCR products overlapped in the HA epitope tag.
Overlapping PCR was used to combine these two fragments.
Using the pDC-attB-var3(HA), plasmid, we incorporated the attB site (5'-AGGCTTGTCGACGACGGCGGTCTCCGTCGTCAGGATCATCTA) just upstream of the IT4var3 open reading frame (ORF). By PCR amplification we also created a 5' NotI site and 3' BamHI, SphI, and PstI sites.
These amplified fragments were inserted into a pGEM-T plasmid containing the ef-1α 5' UTR, and were placed downstream of the promoter using the NotI and PstI cloning sites. The IT4var3 attB-and HA-tagged gene elements were inserted into pDClink together with the ef-1α promoter in a head-to-head fashion with the hdhfr selectable marker cassette using the SphI enzyme.
Plasmids containing the attP element were generated from a second attB-containing plasmid made concurrently with pDC-attB-var3(HA). This plasmid, termed pDC-var3(attB-HA), was generated as above, except that the attB element was inserted prior to the HA epitope within the IT3var3 ORF. To generate the attP-containing plasmids, first a BamHI/BglII fragment containing the attB site, the HA epitope, and codons 212 to 900 of the genomic sequence information is still incomplete, therefore the sequence of the downstream primer was derived from PFA0015c, the homolog of IT4var3 in 3D7 parasites). A XhoI-digested GFP fragment was then prepared by PCR amplification from pLN-GFP , using primers 2023b and 2022 to remove the stop codon and add XhoI sites at either end. This fragment was inserted into the XhoI site of this plasmid to generate p-attP-NTS-V5-GFP-TM-ATS. Plasmid p-attP-NTS-V5-GFP was then created by replacing the NcoI/BamHI fragment containing the TM-ATS 3' UTR region of the transgene with a NcoI/BamHI fragment isolated from pLN-GFP and consisting of the 3' portion of the GFP ORF and the hsp86 3' UTR. To generate the plasmid pattP-NTS-V5-GFP-TM-ATS-hsp86, a ClaI/AflII fragment containing the 3' ORF of IT4var3 was engineered to include an AflII site at the stop codon, by PCR amplification from the p-attP-NTS-V5-GFP-TM-ATS plasmid using primers 1558 and 1557 and subcloning the fragment into pCR2.1 (Invitrogen). This plasmid was opened with AflII plus XbaI and an AflII/XbaI digested fragment containing the hsp86 3' UTR (obtained from pLN-GFP) was inserted. Following XbaI and Klenow digestion to create a blunt 3' end, a fragment containing the 3'-ORF and hsp86 3' UTR was released by digestion with ClaI. This fragment was ligated into p-attP-NTS-V5-GFP-TM-ATS prepared in the same fashion but with a blunt-ended BamHI 3' flanking site. The plasmid p-attP-NTS-V5-TM-ATS-GFP was generated from p-attP-NTS-V5-GFP by the insertion of an IT4var3 1.6 kb XhoI fragment that was PCR-amplified from p-attP-NTS-V5-GFP-TM-ATS with primers 2021 and 1556r (removing the stop codon to enable the 3' addition of GFP).
Plasmids p-attP-NTS-V5-GFP, p-attP-NTS-V5-GFP-TM-ATS, p-attP-NTS-V5-GFP-TM-ATS-hsp86, and pattP-NTS-V5-TM-ATS-GFP were digested with SpeI to accept a 1.7 kb heterologous P. falciparum hrp3
promoter. This promoter sequence was generated from pLN-GFP by PCR amplification using primers 1721 and 1722 to introduce 5' AvrII and 3' SpeI sites. Upon ligation into the attP vectors, the 5' AvrII site ligated with the 5' SpeI overhanging end, allowing for directional discrimination of inserts and retention of a unique SpeI site. These plasmids are denoted by the term "hrp3", such that p-attP-NTS-V5-GFP becomes p-attP-hrp3-NTS-V5-GFP, etc. The attP-containing plasmids p-attP-hrp3-NTS-V5-GFP-TM-ATS-CBD and p-attP-hrp3-NTS-V5-TM-ATS-GFP-CBD are depicted in Supplementary Fig. S4A , B.
p-attP-hrp3-A4var-V5-TM-ATS-GFP and p-attP-hrp3-R29var-V5-TM-ATS-GFP were generated from the plasmid p-attP-hrp3-NTS-V5-TM-ATS-GFP by replacement of the NTS fragment with the respective head structures of var genes A4var or R29var, using the enzymes AvrII and SpeI. p-attP-hrp3-R29var-V5-GFP-TM-ATS was generated from the plasmid p-attP-hrp3-NTS-V5-GFP-TM-ATS-hsp86 in the same fashion. The
A4var head structure consisted of the first 846 codons encoding the DBL1α and CIDR1α domains (PCR amplified from A4 genomic DNA using primers SK1 and SK2), while the R29var head structure consisted of the first 787 amino acids containing the DBL1α1 and CIDR1α1 domains (PCR amplified from A4 genomic DNA using primers SK3 and SK4).
The drug selectable marker CBD (consisting of a 0.6 kb calmodulin 5' UTR driving the blasticidin S-deaminase gene with a P. berghei DT 3' UTR) was isolated from plasmid pCBD-P by NotI digestion, and ligated into the NotI site of the attP plasmids listed above.
CD36 and CSA binding assays
Petri dishes were first coated with 10 µl spots of either 0.1 mg/ml CSA or 0.05 mg/ml CD36-Fc (R&D Systems) overnight at 4˚C. Dishes were then incubated with 2% BSA in 1 × PBS pH 7.4 for 1 hour at 37˚C. The PBS-BSA solution was then removed and 10 µl red blood cells (RBCs) were added on top of the coated spots at a concentration of 10 7 infected RBCs/ml. After 2 hours at 37˚C, we removed non-adherent RBCs by gentle washing with culture medium prewarmed to 37°C. Adherent RBCs were fixed with 1% glutaraldehyde and the numbers of adherent infected RBCs per mm 2 were determined on a Olympus CKX41 microscope at 100 × magnification.
Rosetting assay
To test for rosetting, parasite cultures at 1 % hematocrit were rotated for 15 minutes at 10 rpm/minute at room temperature in the presence of 1 µg/ml ethidium bromide. A drop of cell suspension was then placed on a slide, covered by a coverslip and analyzed with a Nikon Eclipse E600 microscope. Ethidium bromide staining of parasite DNA was used to identify infected RBCs and brightfield images used to determine the presence of bound uninfected RBCs.
Trypsin digestion assay
Infected erythrocytes at the trophozoite stage were incubated for 20 minutes at 37°C with the following concentrations of TPCK-treated trypsin (Sigma) in 1xPBS: 1 mg/ml, 0.1 mg/ml, and 0.01 mg/ml. After trypsinization, cells were incubated with soybean trypsin-chymotrypsin inhibitor (Sigma) for 5 minutes at room temperature and processed for flow cytometry analysis as described in the materials and methods section in the main text.
Electron tomography
Immunolabeled sections of R29-V5-TM-ATS-GFP were prepared as described in the main materials and methods. Tilt series were taken at 11500 × magnification at room temperature with a liquid nitrogen-cooled Table S1 . List of plasmids generated for this study. express mini-var NTS-V5-TM-ATS by ef-1a promoter none p-attP-NTS-V5-GFP-TM-ATS express mini-var NTS-V5-GFP-TM-ATS by ef-1a promoter none p-attP-NTS-V5-GFP express mini-var NTS-V5-GFP by ef-1a promoter none p-attP-NTS-V5-GFP-TM-ATS-hsp86 express mini-var NTS-V5-GFP-TM-ATS by ef-1a promoter none p-attP-NTS-V5-TM-ATS-GFP express mini-var NTS-V5-TM-ATS-GFP by ef-1a promoter none p-attP-NTS-V5-GFP-CBD express mini-var NTS-V5-GFP by ef-1a promoter bsd p-attP-NTS-V5-GFP-TM-ATS-CBD express mini-var NTS-V5-GFP-TM-ATS by ef-1a promoter bsd p-attP-NTS-V5-GFP-TM-ATS-hsp86-CBD express mini-var NTS-V5-GFP-TM-ATS by ef-1a promoter bsd p-attP-NTS-V5-TM-ATS-GFP-CBD express mini-var NTS-V5-TM-ATS-GFP by ef-1a promoter bsd p-attP-hrp3-NTS-V5-GFP express mini-var NTS-V5-GFP by hrp3 promoter none p-attP-hrp3-NTS-V5-GFP-TM-ATS-hsp86-CBD express mini-var NTS-V5-GFP-TM-ATS by hrp3 promoter none p-attP-hrp3-NTS-V5-TM-ATS-GFP express mini-var NTS-V5-TM-ATS-GFP by hrp3 promoter none p-attP-hrp3-NTS-V5-GFP-CBD express mini-var NTS-V5-GFP by hrp3 promoter bsd p-attP-hrp3-NTS-V5-GFP-TM-ATS-hsp86-CBD express mini-var NTS-V5-GFP-TM-ATS by hrp3 promoter bsd p-attP-hrp3-NTS-V5-TM-ATS-GFP-hsp86-CBD express mini-var NTS-V5-TM-ATS-GFP by hrp3 promoter bsd p-attP-hrp3-A4var-V5-TM-ATS-GFP express mini-var A4var-V5-TM-ATS-GFP by hrp3 promoter none p-attP-hrp3-R29var-V5-GFP-TM-ATS-hsp86 express mini-var R29var-V5-GFP-TM-ATS by hrp3 promoter none p-attP-hrp3-R29var-V5-TM-ATS-GFP express mini-var R29var-V5-TM-ATS-GFP by hrp3 promoter none p-attP-hrp3-A4var-V5-TM-ATS-GFP-CBD express mini-var A4var-V5-TM-ATS-GFP by hrp3 promoter bsd p-attP-hrp3-R29var-V5-GFP-TM-ATS-hsp86-CBD express mini-var R29var-V5-GFP-TM-ATS by hrp3 promoter bsd p-attP-hrp3-R29var-V5-TM-ATS-GFP-CBD express mini-var R29var-V5-TM-ATS-GFP by hrp3 promoter bsd dhfr, dihydrofolate reductase; bsd, blasticidin S-deaminase Graph showing the number of infected red blood cells adherent to either spotted CSA or spotted recombinant CD36-Fc. CS2 and A4 are isogenic control parasite lines that bind to the host receptors CSA and CD36 respectively. The A4var-V5-TM-ATS-GFP, R29var-V5-TM-ATS-GFP and R29var-V5-GFP-TM-ATS parasite lines were panned six times on the CSA receptor prior to assessing binding to CD36 and CSA, and had switched to VAR2CSA as the endogenous PfEMP1 protein. 
